Latest Archimedes Pharma Ltd. Stories
READING, England and BEDMINSTER, N.J., June 30, 2011 /PRNewswire/ -- Archimedes Pharma Ltd., and its subsidiary, Archimedes Pharma U.S. Inc., today announced that the U.S.
READING, England, January 17, 2011 /PRNewswire/ -- Archimedes Pharma Ltd., a leading international specialty pharma company, today announced the decision by the Scottish Medicines Consortium (SMC) to accept PecFent(R) (fentanyl pectin nasal spray) for use within NHS Scotland.
READING, England, September 1, 2010 /PRNewswire/ -- Archimedes Pharma Ltd., a leading international specialty pharma company, today announced that the European Commission has granted marketing authorisation for its lead product, PecFent*, an innovative fentanyl nasal spray for the treatment of breakthrough cancer pain (BTCP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough cancer pain is sudden, unpredictable episodes of pain that are...
STOCKHOLM, Sweden, April 29 /PRNewswire/ -- - Results to be Presented at World Congress of Nephrology 2009 Pharmalink AB announced today that it has completed its open Phase II trial evaluating the efficacy and safety of Nefecon(R) in IgA nephropathy, a glomerulonephritis leading to end-stage renal disease.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).